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ABSTRACT
Objective: To assess the association between features
of acute sore throat and the growth of streptococci
from culturing a throat swab.
Design: Diagnostic cohort.
Setting: UK general practices.
Participants: Patients aged 5 or over presenting with
an acute sore throat. Patients were recruited for a
second cohort (cohort 2, n=517) consecutively after
the first (cohort 1, n=606) from similar practices.
Main outcome: Predictors of the presence of
Lancefield A/C/G streptococci.
Results: The clinical score developed from cohort 1
had poor discrimination in cohort 2 (bootstrapped
estimate of area under the receiver operator
characteristic (ROC) curve (0.65), due to the poor
validity of the individual items in the second data set.
Variables significant in multivariate analysis in both
cohorts were rapid attendance (prior duration 3 days or
less; multivariate adjusted OR 1.92 cohort, 1.67 cohort
2); fever in the last 24 h (1.69, 2.40); and doctor
assessment of severity (severely inflamed pharynx/
tonsils (2.28, 2.29)). The absence of coryza or cough
and purulent tonsils were significant in univariate
analysis in both cohorts and in multivariate analysis in
one cohort. A five-item score based on Fever,
Purulence, Attend rapidly (3 days or less), severely
Inflamed tonsils and No cough or coryza (FeverPAIN)
had moderate predictive value (bootstrapped area
under the ROC curve 0.73 cohort 1, 0.71 cohort 2) and
identified a substantial number of participants at low
risk of streptococcal infection (38% in cohort 1, 36%
in cohort 2 scored ≤1, associated with a streptococcal
percentage of 13% and 18%, respectively). A Centor
score of ≤1 identified 23% and 26% of participants
with streptococcal percentages of 10% and 28%,
respectively.
Conclusions: Items widely used to help identify
streptococcal sore throat may not be the most
consistent. A modified clinical scoring system
(FeverPAIN) which requires further validation may be
clinically helpful in identifying individuals who are
unlikely to have major pathogenic streptococci.
BACKGROUND
Antibiotic resistance is a major public health
problem driven largely by antibiotic prescrib-
ing in primary care1 2 and it is important to
minimise antibiotic use in patients who will
not beneﬁt.3 However, antibiotics are still pre-
scribed in the majority of patients with acute
sore throat, the commonest upper respiratory
infection to present in primary care.4
Management of acute sore throat is often
based on features associated with Lanceﬁeld
group A β-haemolytic streptococci (GABHS),
and clinical scores to predict GABHS have
ARTICLE SUMMARY
Strengths and limitations of this study
▪ This was one of the largest studies until now to
develop a clinical score for streptococcal infection.
▪ Two data sets were used to determine the most
consistent variables.
▪ Bootstrapping techniques were used to limit
overfitting, but the score requires further
validation.
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shown promise to be useful5–7 including the simple
‘Centor’criteria—3 of 4 of pus, cervical nodes, a history
of fever and no history of cough. These criteria are
widely advocated in clinical practice guidance,8–12 have
some validation in large routinely collected data sets13
and are probably reasonably calibrated.14 However,
concern has been raised about their use in low preva-
lence settings such as primary care,14 and these criteria
have low speciﬁcity9 leading to high rates of overall anti-
biotic use.9 Furthermore, small studies in typical primary
care settings have suggested that other features might be
useful in reﬁning the criteria—such as shorter prior dur-
ation, severity of pain and muscle ache.7 15 The issue of
which variables most strongly predict streptococcal infec-
tions is therefore still not settled.
We previously reported evidence that group C and G
streptococci present in a similar manner to group A16
and found that some of the variables which comprise
very commonly used clinical prediction rules (such as
purulence) might not be signiﬁcant, and other variables
not commonly used might be important (such as speed
of presentation and severity of inﬂammation). This sug-
gests that conﬁrmation is needed regarding which vari-
ables are important and the need to assess a wide range
of potential variables in different data sets.
We compare ﬁndings from a new cohort with the ori-
ginal cohort16 regarding the predictors of the presence
of pathogenic streptococci including groups A, C and G
in throat swab cultures from patients presenting with
sore throat in primary care.
METHODS
This study was designed to assess not only the validation
characteristics of ﬁve widely available rapid streptococcal
antigen tests (not reported here), but also which clinical
variables were associated with streptococcal infection.
The inclusion criteria, clinical data collection and the
collection and transport of swabs have been described
previously16 but will be summarised.
Inclusion
The target group were patients aged 5 years and over
presenting to primary care clinicians with an acute sore
throat (<2 weeks), where the sore throat was the pre-
dominant clinical feature (or where the clinician felt
that the pharyngitis was driving the illness presentation),
and with an abnormality on examination (erythema or
pus of the throat—similar to a previous study in primary
care17). Exclusions were where the clinician judged
there were other causes of sore throat (eg, aphthous
ulceration, candida and drugs) or unable to consent
(eg, dementia and uncontrolled psychosis).
Clinical data
Following informed consent, baseline clinical data were
collected by the health professional. The clinical proforma
collected information on age; gender; current smoking
status; history of quinsy; data on symptom severity for the
symptoms of sore throat, difﬁculty swallowing, fever,
cough, coryza (‘runny nose’) headache, muscle ache,
abdominal pain, diarrhoea, vomiting, earache (each
symptom was rated 0 no problem; 1 slight problem; 2 mod-
erately bad problem; 3 severe problem); and examination
for oral temperature using Tempadot thermometers,18 the
severity of tonsillar and pharyngeal inﬂammation, the
presence of cervical glands, tonsillar exudate, fetor and
palatal oedema. Patients then completed a daily symptom
diary until symptom resolution (not reported here).
Throat swabs
A throat swab was sent to a central laboratory, where
culture and sensitivity were performed for all signiﬁcant
pathogens in line with National Standard Operating
Proceedures.19 20 The mean time between specimen col-
lection and receipt at the laboratory was 2.9 days (data
incomplete for 13 samples). A swab was inoculated onto
a blood agar plate and a staph/strep agar plate (E&O
Laboratories Ltd, Bonnybridge, Scotland) and spread
for single colonies. Plates were incubated anaerobically
for 48 h.19 20 Plates were read after 24 h incubation and
negative cultures reincubated for an additional 24 h.
Suspected β-haemolytic streptococcal isolates were iden-
tiﬁed by a visual analysis of colony morphology and
Lanceﬁeld grouping (PathoDx Strep Grouping Kit,
Oxoid, UK), in accordance with the National Standard
Operating Procedures.19 20 Antibiotic sensitivities were
conducted using disc diffusion techniques.21
Sample size
In order to determine the association of clinical vari-
ables with streptococcal infection, assuming that at least
one-third of individuals would have streptococci (based
on our ﬁrst data set), and that variables in the strepto-
coccal group were found in 30–80% of individuals, then
to detect a variable with an OR of 2 required 407 indivi-
duals with complete results.
Analysis
Primary analysis
Our original intention was to use a traditional ‘sequen-
tial’approach to the development and validation of clin-
ical scores—to develop them in one data set, and due to
the problem of overﬁtting in one data set, to then valid-
ate in another data set. However, some variables
included in the score from the ﬁrst data set did not
perform well in the second data set (severity of sore
throat, cervical glands) and some variables not included
in the ﬁrst score were signiﬁcant in the second data set
(fever and pus). This poor consistency resulted in very
poor discriminatory performance of the ﬁrst clinical
score when used in the second data set. Since one data
set was clearly insufﬁcient to identify consistent variables,
we used both data sets to identify variables and used
bootstrapping to overcome the problem of overﬁtting.
We have shown previously from the ﬁrst data set that
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patients with group C and G β-haemolytic strains pre-
sented with similar clinical features to individuals with
group A β-haemolytic strains. We ﬁrst assessed the inde-
pendent clinical features associated with combined
group A, C and G streptococci in both data sets. Clinical
variables were included in a logistic regression model to
assess their association with the presence of Lanceﬁeld
group A, C and G streptococci. Forward selection was
used: variables were included if signiﬁcant at the 10%
level and retained in multivariate analysis if they
remained signiﬁcant at the 5% level. Missing variables
were not imputed. Continuous variables were dichoto-
mised using previous cut-offs (age 10 or less; prior dur-
ation longer than the median of 3 days7). Given the
much higher asymptomatic carriage rates of streptococci
in children,22 we did not include age in the ﬁnal multi-
variate models. Clinical scoring systems or clinical pre-
diction rules are most likely to be useful if they are
simple to remember and use, which suggests that few
variables should be used—preferably using a simple
count of the predictive variables. We estimated the
increase in area under the receiver operator characteris-
tic (ROC) curve starting with the most predictive vari-
ables, with the aim of maximising the area under the
curve (AUC) without including unnecessary variables,
and generated a basic model using variables that were
signiﬁcant in multivariate analysis in both data sets.
However, a clinical score using very few variables will
potentially limit the grading of risk (since there will be
fewer categories) and variable performance of one item
in different cohorts will unduly affect validity. Hence, we
also generated a score to include variables that were sig-
niﬁcant in univariate analysis in both data sets and multi-
variate analysis in at least one of the data sets.
Because any new model developed from a single data
set may be overﬁtted, bootstrapped estimates are pro-
vided for the area under the ROC curve for internal val-
idation for the new model (see table 2).23 For the
Centor criteria (an established model), non boot-
strapped estimates are provided.
Calibration
We assessed calibration of the scores by assessing the dif-
ferences between the observed and expected percen-
tages of streptococci using the χ2 test.
Secondary analyses
We also presented the results of alternative analyses (A)
the sequential approach of generating a prediction rule
in one data set and validating it in the second or (B)
the combined approach: using a combined data set for
greater power.
We also explored other approaches to variable selec-
tion such as using the criterion of being signiﬁcant in
univariate analysis in both data sets (which resulted in
the same variable selection), exploring the impact of
variable omission and substitution, and assessing the dis-
crimination comparing the model having the exact
logistic coefﬁcients for each variable with the simple
clinical score (ie, a score which comprised a simple
count of the variables).
RESULTS
The recruitment rate was estimated during the recruit-
ment of the ﬁrst cohort: the median recruitment (the
number of patients/months recruiting) was 4.7 patients/
month—close to the expected rate from national data.24
Patients from higher recruiting doctors (higher than the
median—average 11.8 patients/month) compared with
lower recruiting doctors (an average 2.6 patients/month)
had very similar number of features that predict strepto-
coccal infections (respectively a mean of 3.3 features and
3.4 features using the streptococcal score developed from
the ﬁrst data set), suggesting little or no recruitment bias
based on clinical characteristics in these practices. Both
cohorts used very similar practices: for the ﬁrst data set, we
recruited patients from 15 practices, and for the second
data set, 12 of these 15 practices participated.
Patients were recruited from January 2007 until
October 2008 (96% of patients were recruited after
January 2008 when the ﬁrst data set was completed). All
517 patients recruited in the second data period had
some usable data, and complete data were available in
460 patients. In the second data set, pathogenic strepto-
cocci were found in 207 patients (40%), mainly A (143),
C (30) and G (20) with some B (9), D (2) and F (3).
These are very similar ﬁgures to the ﬁrst data set.16
Primary analyses
The independent variables associated with Lanceﬁeld
group A, C or G streptococci in the second data set are
shown in table 1, with the univariate and multivariate
ORs also reported from the ﬁrst data set for ease of com-
parison. The clinical features predicting the signiﬁcant
presence of group A, C or G β-haemolytic streptococci
in multivariate analysis in both data sets were rapid
attendance (a short prior illness duration of 3 days or
less; multivariate adjusted OR in the ﬁrst data set 1.92;
1.67 in the second data set), fever in the last 24 h (ORs
1.69 and 2.40, respectively) and doctor assessment of
severity of inﬂammation (severely inﬂamed tonsils: 2.28;
2.29). Additional variables signiﬁcant in univariate ana-
lysis in both data sets as well as in multivariate analysis in
at least one of the data sets were items suggesting a
purely pharyngeal illness (the absence of coryza and the
absence of cough), purulent tonsils and muscle aches.
‘Absence of coryza’ performed only marginally better
than ‘absence of cough’ in the two data sets, so based
on the similarity of these items and their performance,
the helpful concept for clinicians of a purely oropharyn-
geal illness (ie, when both cough and coryza are absent)
and the prior extensive use of ‘absence of cough’ in the
Centor criteria, the consensus among the study team
was to use the combined variable ‘absence of cough or
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Table 1 Second data set: clinical variables in patients with Lancefield groups A, C and G compared with patients having no growth of Lancefield groups C, G or A
streptococci, with ORs (95% CI)
Second data set First data set
With streptococci No streptococci Univariate OR *Multivariate OR Univariate OR Multivariate OR
Prior duration ≤3 days 102/176 (58%) 126/308 (41%) 1.99 (1.37 to 2.90) 1.67 (1.10 to 2.54) 2.64 (1.82 to 3.82) 1.92 (1.26 to 2.92)
Cervical glands 150/188 (80%) 245/318 (77%) 1.18 (0.76 to 1.83) 1.20 (0.67 to 2.16) 4.27 (2.41 to 7.57) 2.93 (1.55 to 5.52)
Severely inflamed tonsils 38/167 (23%) 23/294 (8%) 3.47 (1.99 to 6.07) 2.29 (1.23 to 4.26) 3.62 (2.32 to 5.64) 2.28 (1.39 to 3.74)
Absence of runny nose (coryza) 149/193 (77%) 197/323 (61%) 1.58 (1.22 to 2.05) 1.91 (1.21 to 3.00) 2.17 (1.48 to 3.17) 1.55 (0.99 to 2.41)
Age group ≤10 years 12/176 (7%) 18/308 (6%) 1.18 (0.55 to 2.51) 0.80 (0.35 to 1.83) 2.54 (1.50 to 4.29) 1.95 (1.05 to 3.62)
Very bad sore throat 167/193 (87%) 283/323 (88%) 0.91 (0.53 to 1.54) 1.08 (0.44 to 2.68) 4.16 (1.75 to 9.87) 3.31 (1.24 to 8.83)
Absence of cough 127/193 (66%) 167/324 (52%) 1.81 (1.25 to 2.61) 1.11 (0.70 to 1.75) 3.83 (2.35 to 6.25) 2.73 (1.56 to 4.76)
Purulent tonsils 98/192 (51%) 93/323 (29%) 2.58 (1.78 to 3.74) 1.75 (1.13 to 2.72) 2.51 (1.75 to 3.60) 1.06 (0.67 to 1.66)
Fever (last 24 h) 137/193 (71%) 168/324 (52%) 2.27 (1.55 to 3.32) 2.40 (1.52 to 3.77) 2.80 (1.86 to 4.21) 1.69 (1.05 to 2.71)
Muscle aches 111/176 (63%) 150/307 (49%) 1.79 (1.22 to 2.61) 1.31 (0.85 to 2.01) 2.02 (1.39 to 2.94) 2.20 (1.41 to 3.42)
Headache 128/193 (66%) 200/323 (62%) 1.21 (0.83 to 1.76) 1.15 (0.72 to 1.84) 2.00 (1.36 to 2.96) 1.41 (0.89 to 2.25)
Absence of cough or coryza 110/193 (57%) 137/323 (42%) 1.80 (1.25 to 2.58) 1.36 (0.89 to 2.08) 2.66 (1.85 to 3.81) 2.45 (1.62 to 3.68)
*All multivariate estimates adjusted for other significant predictors in each data set.
Estimates of the univariate and multivariate analyses in the first data set are also shown for comparison.
When assessing the combined variable ‘absence of cough or coryza’, the individual items are omitted.
Table 2 Sequential area under the receiver operator characteristic (ROC) curve as successive variables are added (p values given for comparison with previous model
unless specified)
Model
1 2 3 4 5 6 Centor
Severely inflamed
tonsils +Short duration
+Fever in the last
24 h +Pus
+No cough or
coryza +Muscle aches Vs model 5
Second data
set (p)
0.575 (0.538, 0.612) 0.644 (0.596, 0.692)
(p=0.006)
0.689 (0.634, 0.738)
(p=0.003)
0.702 (0.651, 0.748)
(p=0.104)
0.713 (0.661, 0.758)
(p=0.803)
0.708 (0.668, 0.762)
(p=0.334)
0.650 (0.600, 0.700)
(p=0.123)
First data
set (p)
0.602 (0.562, 0.641) 0.676 (0.631, 0.720)
(p=<0.001)
0.706 (0.660, 0.751)
(p=0.017)
0.713 (0.665, 0.761)
(p=0.597)
0.735 (0.690, 0.779)
(p=0.025)
0.738 (0.705, 0.791)
(p=0.143)
0.716 (0.674, 0.758)
(p=0.291)
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coryza’ which also performed marginally better than
either alone.
Table 2 shows the incremental performance in terms
of area under the ROC curve as successive variables are
added to the models in both data sets. There is modest
improvement in AUC after the ﬁrst three variables are
added, and no improvement when the sixth variable
(muscle aches) is added. However, if a basic score
(model 3) is used, the grading of risk at lower scores is
crude as few patients can be categorised as lower risk:
only 19% of the ﬁrst data set and 22% of the second
data set score 0 and 15% and 22%, respectively, of these
groups have streptococci (see online supplementary
appendix 1 for the full table).
A Centor score of ≤1 was identiﬁed among 23% in the
ﬁrst cohort and 26% of the second cohort and strepto-
coccal percentages were isolated in 10% and 28% of
these groups, respectively (see table 3). By comparison,
the extended ﬁve point score—Fever, Purulence, Attend
rapidly (3 days or less), severely Inﬂamed tonsils and No
cough or coryza (FeverPAIN; model 5 from table 2) pro-
vides a ﬁner grading of risk and signiﬁcantly more
patients in both cohorts can be categorised as being at
low risk of streptococcal infection (<20% chance of
streptococci, see table 3): using the modiﬁed FeverPAIN
score, there were more than 30% of patients scoring ≤1
(ﬁrst data set 38%; second data set 36%) and fewer of
these patients (13% and 18%, respectively) had strepto-
cocci, shown graphically in ﬁgure 1.
Calibration
FeverPAIN calibrated well in both data sets, with no sig-
niﬁcant differences between the percentages of observed
and predicted presence of streptococci. The calibration
of the Centor criteria was good in the ﬁrst data set but
poor in the second data set with signiﬁcant differences
between the percentages of observed and predicted
presence of streptococci at low scores (see online sup-
plementary appendix 2).
The ‘sequential’ approach of developing the ﬁrst
score and then testing it in the second data set demon-
strated poor performance of the ﬁrst score in the
second data set. The approach of using a combined data
set to provide more power generated an eight-item
unwieldy score and obscured the major differences in
performance between the data sets (see online supple-
mentary appendix 3 for details).
DISCUSSION
This study provides evidence to conﬁrm that streptococ-
cal sore throats are currently common in primary care
and that Lanceﬁeld groups C and G make up a quarter
of streptococcal sore throats. The study also conﬁrms
that the best predictors of streptococcal infection may
not include some of the features traditionally used, and
that traditional scoring systems may have limited clinical
utility in identifying individuals who have a low likeli-
hood of streptococcal infection that is, who do not need
to have antibiotics.
Strengths and limitations of the study
These data sets are some of the largest from a typical
primary care setting to have assessed the importance of
the range of streptococci, and to have explored the
range of potential clinical predictors of streptococcal
infection. There were few missing data (less than 5% for
any analysis), and little evidence of recruitment bias
either in recruitment rates or clinical characteristics.
The conventional approach of developing and validating
a diagnostic model is to develop it in one data set and
test it in another. However, the variability of perform-
ance of variables in these data sets and the poor
Table 3 Number of individuals with Lancefield groups A, C or G streptococci (%) at each level of clinical scores, and the
total number of individuals at each level (and % of the total sample). <: Please check table haeding italic words.>
Clinical score 0 1 2 3 4+ Total
First data set
FeverPAIN score
Streptococci 7 (11%) 21 (14%) 45 (30%) 40 (39%) 62 (62%) 175 (31%)
Total 63 (11%) 155 (27%) 149 (26%) 103 (18%) 100 (17%) 570 (100%)
Centor score
Streptococci 3 (7%) 10 (11%) 45 (23%) 65 (43%) 55 (57%) 178 (31%)
Total 45 (8%) 88 (15%) 199 (34%) 152 (26%) 97 (17%) 581 (100%)
Second data set
FeverPAIN score
Streptococci 9 (19%) 22 (18%) 46 (35%) 41 (48%) 49 (65%) 167 (36%)
Total 48 (10%) 121 (26%) 130 (28%) 86 (19%) 75 (16%) 460 (100%)
Centor score
Streptococci 0 (0) 36 (32%) 36 (23%) 69 (50%) 47 (58%) 188 (37%)
Total 15 (3%) 114 (23%) 157 (31%) 138 (27%) 81 (16%) 505 (100%)
Two clinical scores are shown: (1) a modified streptococcal score (model 5; 1 point each for: Fever during the last 24 h, Purulent tonsils,
Attend rapidly (3 days or less), very Inflamed throat and No cough or coryza (FeverPAIN)) and (2) for comparison the Centor score (1 point
each for pus, fever in the last 24 h, cervical glands and the absence of cough).
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discriminatory performance of the ﬁrst score when used
in the second data set suggest that such an approach is
unlikely to provide the most reliable method of variable
selection for a clinical prediction rule, supported by
similar ﬁndings in the development of clinical predic-
tion rules for other acute infections.25 This suggests that
the choice of variables to include in clinical prediction
models preferably should be based on multiple cohorts
at different times and/or different settings. The alterna-
tive approach of combining data sets to increase power
generated an eight-variable score with improved discrim-
ination but is unwieldy for clinical purposes. The com-
bined data set also hid the considerable variability
between data sets in performance of both individual
variables and also of the ﬁrst score. Further support for
the poor clinical utility of the ﬁrst score comes from the
trial,26 which demonstrates that using the ﬁrst score does
not signiﬁcantly improve outcomes, similar to a previous
trial of the Centor criteria which also demonstrated no
impact on antibiotic use.27 Over and above the most
basic model (short prior duration, severe inﬂammation,
fever), the choice of additional variables to include (pus
and ‘absence of cough and coryza’) was determined by
consensus, including a consideration of the strength of
prior evidence, but omission of key variables or substitu-
tion did not have major effects on the discrimination.
Although we have provided bootstrapped estimates of
the area under the ROC curve to limit overﬁtting, never-
theless the proposed model should have further
validation.15
Main findings in the context of previous literature
Group A β-haemolytic streptococci have dominated pre-
vious literature due to their association with major non-
suppurative adverse outcomes—particularly rheumatic
fever and glomerulonephritis.5 Hence, the clinical pre-
dictors of group A infection5 6 7—especially pus, cervical
nodes, a history of fever and no history of cough—have
been widely used in clinical guidelines.8 10 22 Trials
using these as inclusion criteria may have larger effect
sizes for antibiotics than trials using less selected patients
—although the validity of historical comparisons is ques-
tionable.28 We were unable to conﬁrm the importance
of cervical glands as a predictor of streptococcal infec-
tion in the second data set, and in the ﬁrst data set we
were unable to conﬁrm the importance of purulence.7 9
From these two data sets, the features that may be most
important are the speed of presentation (ie, symptoms
developing rapidly resulting in a short prior duration of
illness), the severity of tonsillar inﬂammation and fever.
These variables have been identiﬁed in studies from
typical primary care settings,7 15 but previous studies
have been limited by the lack of multivariate analysis or
limited power.
Clinical utility
Scoring systems are most helpful clinically for reducing
antibiotic use if they identify as large a group as possible
of individuals unlikely to have Streptococcus. From these
data sets, the Centor criteria are likely to identify rela-
tively few such individuals who do not have streptococci:
only 23% in the ﬁrst data set and 26% in the second
data set had a score ≤1, and in the second data set the
percentage of streptococci was high (28%). A low count
(≤1) using a modiﬁed score (FeverPAIN) identiﬁed
more than 35% of patients in both data sets who are
unlikely to have streptococci (between 13% and 18%).
CONCLUSION
Items traditionally used to help identify presentations of
streptococcal sore throat in primary care may not be reli-
able. Conventional clinical scoring systems may not be
very helpful clinically in identifying individuals who are
unlikely to have major pathogenic streptococci. A modi-
ﬁed clinical rule developed for targeting Lanceﬁeld
group A, C and G streptococci requires further valid-
ation, but should enable clinicians to target those at
high risk of streptococcal infections and identify more
than one third of those presenting with sore throat as
being at low (<20%) risk of streptococcal infection.
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